923287-50-7

Opicapone is a medication used in conjunction with levodopa and carbidopa (commonly found in medications like Sinemet and Rytary) to address the end-of-dose "wearing-off" symptoms associated with Parkinson's disease. It belongs to the category of catechol-O-methyltransferase (COMT) inhibitors.

Parkinson's disease is a neurodegenerative disorder characterized by both motor and non-motor symptoms. Levodopa is considered the gold standard for symptom management in Parkinson's disease. However, after around two years of treatment, approximately half of patients experience fluctuations in motor performance. This is where COMT inhibitors like Opicapone become essential.

Opicapone, marketed under the brand name Ongentys, is a potent third-generation COMT inhibitor. Its mechanism of action involves inhibiting COMT, an enzyme responsible for metabolizing levodopa. By inhibiting COMT, Opicapone enhances the bioavailability and duration of action of levodopa, leading to more consistent symptom control throughout the day.

Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. Huarong Pharm has built platforms for the research, development and manufacturing of Building Blocks, Reference Compounds & Impurities, Natural products, APIs & Intermediates, Antibody-drug Conjugates (ADCs) and others. To maintain a high innovation efficiency, the company has continuously increased the investment on R&D facilities and state-of-the-art equipment in the past several years, including the establishment of kilogram GMP conditions plants and R&D centers. Huarong Pharm adheres to our vision, our mission, and our value, keeping abreast of the current trend and state-of-the-art science and technologies of the global biopharmaceutical industry to serve our clients to the utmost satisfaction. Our existing advantages have led to our in-depth services for the R&D of small molecule drug discovery.